Phase 1/2 Trial of Medigene’s MDG1011 Immunotherapy in Blood Cancer Patients Set to Begin
A Phase 1/2 clinical trial testing an experimental T-cell therapy for the first time in human patients will begin in the coming weeks after receiving…
Myeloma
New Test Speeds Time to Determine Success of Bone Marrow Transplants
Scientists have developed a new test that shortens the time it takes to assess the success of bone marrow transplants — to a few days…
Myeloma Patients, Advocates Trek to Mt. Everest’s Doorstep to Raise Awareness
To raise awareness of multiple myeloma and funding for research, 18 patients, caregivers, and healthcare professionals have embarked on a challenging ascent to Mount Everest…
Mouse Study Finds Potential Targets to Minimize Risks of Stem Cell Transplants
Immune factors that drive donor T-cells to cause graft-versus-host disease (GVHD) have been found by researchers whose discovery may offer new opportunities for therapeutic…
Xgeva Use in Myeloma May Be Expanded to Europe Following Positive CHMP Opinion
Treatment of bone lesions in multiple myeloma patients with Amgen’s Xgeva (denosumab) may be expanded to European patients following a positive opinion from…
Revlimid Combo Treatment Improved Survival in Newly-diagnosed Myeloma Patients in Phase 3 Trial
Newly diagnosed multiple myeloma patients unable to undergo stem cell transplants lived significantly longer without their disease progressing when given continuous treatment with…
UT Southwestern Researcher Tells His CAR-T Therapy Story Ahead of Myeloma Trial
As UT Southwestern and Celgene Corporation join efforts to launch a new clinical trial to evaluate a chimeric antigen receptor T-cell therapy,…
Adelson Research Foundation Supports 3-Year Myeloma Funding Initiative
The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private organization funding collaborative translational science, recently launched the Adelson Program in…
Pomalyst Combo Delays Disease Progression in Relapsed or Refractory Myeloma Patients in Phase 3 Trial
A combination treatment including Pomalyst (pomalidomide) significantly extended the time until disease progression or death in patients with relapsed or refractory multiple myeloma who were…
PT-112 Receives Orphan Drug Status for Advanced Multiple Myeloma
PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for…
